Matching models to data: A receptor pharmacologist's guide

British Journal of Pharmacology

Volumn 161, Issue 6, 2010, Pages 1276-1290

  Hall, David A ^a   Langmead, Christopher J ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

Data analysis; Drug discovery; Experimental design; Global fitting; Ligand depletion; Mechanistic model; Partial agonist; Receptor pharmacology; Schild analysis; Statistics

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CORTICOTROPIN RELEASING FACTOR; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 8; METHACHOLINE; OXYTOCIN;

BINDING AFFINITY; CALCIUM MOBILIZATION; CHO CELL; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DATA ANALYSIS; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DESIGN; HILL REACTION; HUMAN; ISOTHERM; KERNEL METHOD; MATHEMATICAL MODEL; MEDICAL SPECIALIST; NONHUMAN; NULL HYPOTHESIS; PHARMACOLOGIST; PHARMACOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR BLOCKING; REVIEW; STATISTICAL ANALYSIS; TOTAL QUALITY MANAGEMENT;

ANIMALS; HUMANS; LABORATORY PERSONNEL; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; PROTEIN BINDING; RECEPTORS, DRUG; RESEARCH DESIGN;

EID: 78049414628     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00879.x     Document Type: Review

References (28)

1. Arunlakshana O, Schild HO (1959). Some quantitative uses of drug antagonists. Br J Pharmacol 14: 48-58.
2. Black JW, Leff P (1983). Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220: 141-162.
3. 125I-containing acylating agent. Biochem J 133: 529-539.
4. Burnham KP, Anderson DR (2002). Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach. Springer-Verlag: New York.
5. Chang K-J, Jacobs S, Cuatrecasas P (1975). Quantitative aspects of hormone receptor interactions of high affinity: effect of receptor concentration and measurement of dissociation constants of labelled and unlabelled hormones. Biochim Biophys Acta 406: 294-303.
6. Christopoulos A (1998). Assessing the distribution of parameters in models of ligand-receptor interactions: to log or not to log. Trends Pharmacol Sci 19: 351-357.
7. 4 receptor antagonists on constitutively active wild-type and mutated receptors. Molec Pharmacol 58: 136-144.
8. Colqhoun D (1973). The relation between classical and cooperative models for drug action. In: Rang HP (ed.). Drug Receptors. The Macmillan Company: London, pp. 149-182.
9. De Léan A, Stadel JM, Lefkowitz RJ (1980). A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase coupled β-adrenergic receptor. J Biol Chem 255: 7108-7117.
10. 2+-indicator dyes. Cell Calcium 27: 97-106.
11. Goldstein A, Barrett RW (1987). Ligand dissociation constants from competition binding assays: errors associated with ligand depletion. Mol Pharmacol 31: 603-609.
12. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450.
13. Hall DA (2000). Modelling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two state model of receptor activation. Molec Pharmacol 58: 1412-1423.
14. Hulme EC, Birdsall NJM (1992). Strategy and tactics in receptor binding studies. In: Hulme EC (ed.). Receptor-Ligand Interactions: A Practical Approach. Oxford University Press: Oxford, pp. 63-176.
15. Karlin A (1967). On the application of 'a plausible model' of allosteric proteins to the receptor for acetylcholine. J Theor Biol 16: 306-320.
16. Kenakin TP (2009). A Pharmacology Primer. Elsevier: London.
17. Kuestner RE, Elrod RD, Grant FJ, Hagen FS, Kuijper JL, Matthews SL et al. (1994). Cloning and characterisation of an abundant subtype of the human calcitonin receptor. Molec Pharmacol 46: 246-255.
18. La Rosa GJ, Thomas KM, Kaufmann ME, Mark R, White M, Taylor L et al. (1992). Amino terminus of the IL-8 receptor is the major determinant of receptor subtype specificity. J Biol Chem 267: 25402-25406.
19. Lew MJ, Angus JA (1995). Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci 16: 328-337.
20. Motulsky H (1995). Intuitive Biostatistics. Oxford University Press: New York.
21. Motulsky H, Christopoulos A (2004). Fitting Models to Biological Data Using Linear and Non-Linear Regression: A Practical Guide to Curve Fitting. Oxford University Press: New York.
22. Neote T, Darbonne W, Ogez J, Horuk R, Schall TJ (1993). Identification of a promiscuous inflammatory peptide binding site on the surface of red cells. J Biol Chem 268: 12247-12249.
23. Paton WDM, Rang HP (1966). A kinetic approach to the mechanism of drug action. In: Harper NJ, Simmonds AB (eds). Advances in Drug Research. Academic Press: New York, pp. 57-80.
24. Strange PG (2008). Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol 153: 1353-1363.
25. Swillens S (1995). Interpretation of binding curves obtained with high receptor concentrations: practical aid for computer analysis. Mol Pharmacol 47: 1197-1203.
26. Thron CD (1972). On the analysis of pharmacological experiments in terms of an allosteric model. Molec Pharmacol 9: 1-9.
27. Van Riper G, Siciliano S, Fischer PA, Meurer R, Springer MS, Rosen H (1993). Characterisation and species distribution of high affinity GTP-coupled receptors for human Rantes and monocyte chemoattractant protein 1. J Exp Med 177: 851-856.
28. Wilson S, Chambers JK, Park JE, Ladurner A, Cronk DW, Chapman CG et al. (1996). Agonist potency at the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay. J Pharmacol Exp Ther 279: 214-221.